- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02694458
Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (OPTIBAYE)
Vancomycin is the standard first-line treatment for MRSA infections and a first-line empiric therapy. The relationship between exposure to vancomycin and efficacy is admitted but because of an important intersubject variability, therapeutic exposure isn't usually achieved.
The primary aim of this randomized controlled trial is to evaluate a new early dosage adjustment strategy of vancomycin in children, comparing it to the usual treatment strategy.
Using a bayesian approach, the purpose is to achieve earlier a therapeutic and non-toxic exposure to vancomycin.
The primary hypothesis is that an early dosage adjustment strategy using a bayesian approach will allow patients to achieve the vancomycin pharmacological target faster than with the usual treatment strategy.
Study Overview
Status
Detailed Description
Introduction/ Clinical significance :
Staphylococcus aureus is a common cause of serious infections. Methicillin-resistant Staphylococcus aureus (MRSA) are one of the most common causes of nosocomial antibiotic resistant bacterial infections in the world. According to the last data from the European Antimicrobial Resistance Network, in 2014, 17,4 % of invasive staphylococcal infections are due to MRSA in France, with proportions of up to 56 % in some regions in the European Economic Area (EEA). In the United-States of America, MRSA reach 50 % of Staphylococcus isolates in some studies. Vancomycin is the standard first-line treatment for MRSA infections and a first-line empiric therapy.
To optimize good clinical outcomes for invasive MRSA infections using pharmacokinetics-pharmacodynamics of vancomycin, studies support targeting area under the curve (AUC) of the serum concentration versus time over 24 hours to minimum inhibitory concentration (MIC) ratio ≥ 400, which frequently correlates to a trough concentration of 15 - 20 mg/L when the MIC is 1 mg/L. Because of few consensus regarding the dosage to use and high intersubject variability, this pharmacological target is difficult to reach in children, which may lead to a delayed infection control and an increase of vancomycin toxicity-related side effects.
Aims :
The primary aim is to evaluate an early dosage adjustment strategy of vancomycin in children, comparing it to the usual treatment strategy.
Using a bayesian approach, the main purpose is to achieve earlier a therapeutic and non-toxic exposure to vancomycin.
The secondary aims are to compare with the usual treatment strategy 1) the proportion of subjects with vancomycin serum concentration within the concentration targets at the 24th hour of treatment, and 2) the clinical (in terms of fever), biological (in terms of CRP) and bacteriological (in terms of blood culture) efficacy of this early dosage adjustment strategy of vancomycin.
Hypothesis :
This study hypothesizes that early dosage adjustment strategy of vancomycin using a bayesian approach will be superior to usual treatment strategy in achieving the pharmacological target of vancomycin at the 24th hour of treatment in children.
Methodology :
As part of routine care, a prospective open-label randomized controlled trial will be conducted in a major paediatric hospital in Paris, France. Subjects will be divided into two arms. Each arm will contain 50 subjects.
For subjects of the Modeling arm, drug concentration will be measured at the 3rd hour of treatment and dosage adjustment will be done at the 6th hour of treatment using a bayesian approach. Vancomycin serum concentration will be then measured at the 24th hour of treatment.
Subjects of the control arm will receive the usual treatment strategy. Vancomycin serum concentration will be measured at the 24th hour of treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker-Enfants Malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged 1 months to 16 years
- Children for whom a vancomycin treatment is started in the hospital Necker-Enfants Malades in Paris, France
- No objection of parents and of the child himself if he is able to express it.
Exclusion Criteria:
- Patients undergoing hemodialysis
- Patients undergoing peritoneal dialysis
- Newborns less than 1 months old
- Adolescents more than 16 years old and adults
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Modeling arm
Early vancomycin monitoring and bayesian dosage adjustment
|
Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach.
Then measure of vancomycin serum concentration at the 24th hour of treatment.
|
Sham Comparator: Control arm
Usual vancomycin dose and monitoring strategy
|
Vancomycin serum concentration will be measured at the 24th hour of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with vancomycin AUC/MIC ≥ 400 and serum trough concentration ≤ 20 mg/L
Time Frame: 24th hour of treatment
|
24th hour of treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean-Marc TRELUYER, MD, PhD, Hôpital Necker-Enfants Malades
Publications and helpful links
General Publications
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4. Erratum In: Clin Infect Dis. 2011 Aug 1;53(3):319.
- Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, Capparelli EV. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013 Apr;32(4):e155-63. doi: 10.1097/INF.0b013e318286378e.
- Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG. Achieving therapeutic vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014 Nov;67(6):416-22. doi: 10.4212/cjhp.v67i6.1403.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-A01545-44
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methicillin-resistant Staphylococcal Infections
-
University of Lausanne HospitalsCompletedMethicillin-Resistant Staphylococcus Aureus
-
NorthShore University HealthSystemAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin Resistant Staphylococcus AureusUnited States
-
University of California, IrvineAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
Pinyo RattanaumpawanUnknownMethicillin-Resistant Staphylococcus AureusThailand
-
Mercy ResearchWithdrawnMethicillin-Resistant Staphylococcus Aureus
-
West Virginia UniversityCompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedAntibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients (StaphMRG)Methicillin Resistant Staphylococcus AureusFrance
-
University of FloridaRecruitingMethicillin-Resistant Staphylococcus AureusUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedMethicillin-Resistant Staphylococcus AureusFrance
-
University of Colorado, DenverAmerican Academy of Family Physicians National Research NetworkCompletedMethicillin-Resistant Staphylococcus AureusUnited States
Clinical Trials on Early vancomycin monitoring and bayesian dosage adjustment
-
CR-CSSS Champlain-Charles-Le MoyneCompletedAdult | Vancomycin | Area Under CurveCanada
-
Universidad Autonoma de Nuevo LeonCompletedComplication of Surgical Procedure | Surgical Site InfectionMexico
-
Assistance Publique - Hôpitaux de ParisRecruitingPediatric Kidney Transplant RecipientsFrance
-
Chinese University of Hong KongProfessor Bryan Ping Yen YAN (byan)Recruiting
-
University of FloridaCompleted
-
NURIA LLOBERAS BLANCHCompletedKIDNEY TRANSPLANTATIONSpain
-
Murdoch Childrens Research InstituteSydney Children's Hospitals Network; Royal Children's Hospital; Monash Health; Royal...Not yet recruitingInfections | Sepsis | BacteremiaAustralia
-
Rijnstate HospitalUniversity of Twente; Philips Research EindhovenNot yet recruitingTelemedicine | Acute Pancreatitis | Monitoring | Patient Discharge | HealthdotNetherlands
-
Montreal Heart InstituteRoche Diagnostic Ltd.CompletedQuality of Life | Anticoagulants | Drug Monitoring | Pharmacy | Ambulatory CareCanada
-
Uppsala UniversityActive, not recruitingSepsis | Infection, BacterialSweden